Disc Medicine Inc at Morgan Stanley Global Healthcare Conference Transcript
Okay, good morning, everybody. Welcome, I'm Doug Tsao, Senior Analyst at H.C. Wainwright. We are happy to have with us Disc Medicine, represented by the company's CEO, John Quisel.
It's been an eventful year for the company. First, coming public through its merger with Gemini last year, and more significantly, the release of your first clinical data in patients for your lead asset, bitopertin. So maybe, John, as a starting point, just start with what bitopertin is and the condition, EPP or erythropoietic protoporphyria, the condition, what that entails, how patients are currently treated, and what we saw in the BEACON trial.
Questions & Answers
Yeah, great. Thanks for the introduction and great to be here.
So bitopertin is a drug that we in-licensed from Roche. Roche had actually dosed in over 4,000 patients. And what it does is inhibit the uptake of glycine through a transporter called
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |